Galapagos reported EUR108.07M in Cash and Equivalent for its fiscal quarter ending in March of 2025.


Cash And Equivalent Change Date
argenx SE 2.09B 586.04M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
Genmab DKK 1.3B 323M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 188M 188M Dec/2024
Incyte USD 2.42B 13.08M Jun/2025
Merck EUR 1.17B 161M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sanofi 15.36B 7.37B Jun/2025
UCB EUR 1.57B 1.14B Dec/2024
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025